Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH
Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH · Treatment with pegcetacoplan resulted in a sustained improvement in haemoglobin with a mean increase from baseline of 2.7 g/dL at week 48, which is equal to the 2.7 g/dL increase seen at week 16 with pegcetacoplan-treated patients · Sustained improvements in transfusion avoidance, reticulocyte count, lactate dehydrogenase (LDH) level and Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue score were observed in patients treated with pegcetacoplan ·